Henk V.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Bioavailability and Bioequivalence Assessment of Niraparib and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients
- Phase 3 Randomized Double-Blind Study of INCA33890 Plus First-Line Chemotherapy and Bevacizumab in Metastatic Microsatellite Stable Colorectal Cancer
- (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Data & Insights
Has run more than one trial at 40 of 133 partner sites.
Specializations
Thoracic Oncology
Clinical research in non-small cell lung cancer and small-cell lung cancer, with interest in EGFR- and ALK-driven disease, advanced and metastatic presentations, and perioperative treatment strategies.
- Non-small cell lung cancer
- Small-cell lung cancer
- Advanced and metastatic solid tumors
- Molecularly selected lung cancer
Work in this area also extends to lung cancer cases with KRAS G12C, RET fusion, and other actionable molecular alterations.
Gastrointestinal and Hepatobiliary Cancer
Research activity includes pancreatic cancer, colorectal cancer, gastric cancer, cholangiocarcinoma, and related gastrointestinal malignancies across resectable, locally advanced, and metastatic settings.
- Pancreatic cancer
- Colorectal cancer
- Cholangiocarcinoma
- Gastric and gastroesophageal cancer
There is also involvement in neuroendocrine tumors and peritoneal metastases of gastrointestinal origin.
Genitourinary and Gynecologic Oncology
The investigator is active in urothelial carcinoma, bladder cancer, renal cell carcinoma, prostate cancer, and ovarian cancer, including high-risk and recurrent disease.
- Urothelial carcinoma
- Bladder cancer
- Prostate cancer
- Ovarian cancer
Additional interest is seen in endometrial cancer, cervical cancer, and other gynecologic tumors.
Hematologic Malignancies
Clinical trial involvement covers lymphoma, multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, and other blood cancers.
- Diffuse large B-cell lymphoma
- Multiple myeloma
- Acute myeloid leukemia
- Myelodysplastic syndromes
Research also includes relapsed and refractory hematologic disease and cell therapy-based treatment approaches.
Immuno-Oncology and Targeted Therapeutics
The investigator’s portfolio includes immune checkpoint therapy, CAR T-cell therapy, and targeted therapy across solid and hematologic cancers, with emphasis on biomarker-defined treatment selection.
- Immune checkpoint therapy
- CAR T-cell therapy
- Targeted anticancer therapy
- Biomarker-driven treatment
Related interests include HER2-expressing tumors, FGFR-altered cancers, and other molecularly defined malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.